Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine Pathology
Published in: Endocrine Pathology 1/2012

01-03-2012

From Transcriptional Profiling to Tumor Biology in Pheochromocytoma and Paraganglioma

Authors: Alberto Cascón, Daniel A Tennant

Published in: Endocrine Pathology | Issue 1/2012

Login to get access

Abstract

This review summarizes the way in which inherited mutations define global gene expression in pheochromocytoma (PCC) and paraganglioma (PGL), and how the use of gene expression analysis has advanced our understanding of these diseases. The biology of PCC and PGL tumors is diverse and it has become clear that there is no apparent single biology that defines these tumors. However, over the last 20 years, our understanding of the biology of PGL and PCC has been considerably advanced by the discovery of inherited mutations that predispose individuals to developing the disease. More recently, the use of transcriptomics to stratify tumors based on their gene expression profiles has, in particular, played a vital role in delineating novel mutations involved in the pathogenesis of these tumors. In this review, we describe our current understanding of the biology of cluster 1 (pseudohypoxic) tumors and how mutations that result in the pseudohypoxic phenotype that leads to changes in global gene expression. We also review the advances in our understanding of cluster 2 tumors, and in particular, focus on the newly described MAX tumors.
Literature
1.
Eisenhofer, G., et al., Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocr Relat Cancer, 2004. 11(4): p. 897–911.PubMedCrossRef
2.
Dahia, P.L., et al., Novel pheochromocytoma susceptibility loci identified by integrative genomics. Cancer Res, 2005. 65(21): p. 9651–8.PubMedCrossRef
3.
Huynh, T.T., et al., Transcriptional regulation of phenylethanolamine N-methyltransferase in pheochromocytomas from patients with von Hippel–Lindau syndrome and multiple endocrine neoplasia type 2. Ann N Y Acad Sci, 2006. 1073: p. 241–52.PubMedCrossRef
4.
Burnichon, N., et al., Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Hum Mol Genet, 2011. 20(20): p. 3974–85.PubMedCrossRef
5.
Lopez-Jimenez, E., et al., Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol, 2010. 24(12): p. 2382–91.PubMedCrossRef
6.
Waldmann, J., et al., Microarray analysis reveals differential expression of benign and malignant pheochromocytoma. Endocr Relat Cancer, 2010. 17(3): p. 743–56.PubMedCrossRef
7.
Brouwers, F.M., et al., Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci, 2006. 1073: p. 541–56.PubMedCrossRef
8.
Thouennon, E., et al., Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab, 2007. 92(12): p. 4865–72.PubMedCrossRef
9.
Dahia, P.L., et al., A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet, 2005. 1(1): p. 72–80.PubMedCrossRef
10.
Chi, J.T., et al., Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med, 2006. 3(3): p. e47.PubMedCrossRef
11.
12.
Tian, H., S.L. McKnight, and D.W. Russell, Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev, 1997. 11(1): p. 72–82.PubMedCrossRef
13.
Wang, G.L., et al., Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A, 1995. 92(12): p. 5510–4.PubMedCrossRef
14.
Bruick, R.K. and S.L. McKnight, A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 2001. 294(5545): p. 1337–40.PubMedCrossRef
15.
Epstein, A.C., et al., C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 2001. 107(1): p. 43–54PubMedCrossRef
16.
Hewitson, K.S., et al., The role of iron and 2-oxoglutarate oxygenases in signalling. Biochem Soc Trans, 2003. 31(Pt 3): p. 510–5.PubMed
17.
Favier, J., et al., The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One, 2009. 4(9): p. e7094.PubMedCrossRef
18.
Gottlieb, E. and I.P. Tomlinson, Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer, 2005. 5(11): p. 857–66.PubMedCrossRef
19.
Astuti, D., et al., Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet, 2001. 69(1): p. 49–54.PubMedCrossRef
20.
Bayley, J.P., et al., SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. Lancet Oncol, 2010. 11(4): p. 366–72.PubMedCrossRef
21.
Baysal, B.E., et al., Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 2000. 287(5454): p. 848–51.PubMedCrossRef
22.
Burnichon, N., et al., SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet, 2010. 19(15): p. 3011–20.PubMedCrossRef
23.
Hao, H.X., et al., SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma. Science, 2009. 325(5944): p. 1139–42.PubMedCrossRef
24.
Niemann, S. and U. Muller, Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet, 2000. 26(3): p. 268–70.PubMedCrossRef
25.
Selak, M.A., et al., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 2005. 7(1): p. 77–85.PubMedCrossRef
26.
Guzy, R.D., et al., Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol, 2008. 28(2): p. 718–31.PubMedCrossRef
27.
Lando, D., et al., FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev, 2002. 16(12): p. 1466–71.PubMedCrossRef
28.
Mahon, P.C., K. Hirota, and G.L. Semenza, FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev, 2001. 15(20): p. 2675–86.PubMedCrossRef
29.
Lisy, K. and D.J. Peet, Turn me on: regulating HIF transcriptional activity. Cell Death Differ, 2008. 15(4): p. 642–9.PubMedCrossRef
30.
Cervera, A.M., et al., Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer, 2009. 8: p. 89.PubMedCrossRef
31.
Agger, K., et al., The emerging functions of histone demethylases. Curr Opin Genet Dev, 2008. 18(2): p. 159–68.PubMedCrossRef
32.
Lin, T.Y., et al., Loss of the candidate tumor suppressor BTG3 triggers acute cellular senescence via the ERK-JMJD3-p16(INK4a) signaling axis. Oncogene, 2011.
33.
Sola, S., et al., p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS One, 2011. 6(3): p. e18421.PubMedCrossRef
34.
Qin, Y., et al., Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet, 2010. 42(3): p. 229–33.PubMedCrossRef
35.
Segouffin-Cariou, C. and M. Billaud, Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem, 2000. 275(5): p. 3568–76.PubMedCrossRef
36.
Johannessen, C.M., et al., The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A, 2005. 102(24): p. 8573–8.PubMedCrossRef
37.
Yao, L., et al., Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. JAMA, 2010. 304(23): p. 2611–9.PubMedCrossRef
38.
Zhu, J., J. Blenis, and J. Yuan, Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A, 2008. 105(18): p. 6584–9.PubMedCrossRef
39.
Jimenez, R.H., et al., Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR). PLoS One, 2010. 5(2): p. e9084.PubMedCrossRef
40.
Huang, S.C., et al., Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res, 2000. 60(22): p. 6223–6.PubMed
41.
Huang, S.C., et al., Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab, 2003. 88(1): p. 459–63.PubMedCrossRef
42.
Comino-Mendez, I., et al., Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet, 2011. 43(7): p. 663–7.PubMedCrossRef
43.
Zhang, X., et al., Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. Cancer Res, 2010. 70(6): p. 2350–8.PubMedCrossRef
44.
Astuti, D., et al., Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br J Cancer, 2005. 92(8): p. 1574–80.PubMedCrossRef
45.
Pantoja, C., et al., Inactivation of imprinted genes induced by cellular stress and tumorigenesis. Cancer Res, 2005. 65(1): p. 26–33.PubMed
46.
Zhang, X., et al., A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab, 2003. 88(11): p. 5119–26.PubMedCrossRef
47.
Zhao, J., et al., Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J Clin Endocrinol Metab, 2005. 90(4): p. 2179–86.PubMedCrossRef
Metadata
Title
From Transcriptional Profiling to Tumor Biology in Pheochromocytoma and Paraganglioma
Authors
Alberto Cascón
Daniel A Tennant
Publication date
01-03-2012
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2012
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-012-9195-x

Other articles of this Issue 1/2012

Endocrine Pathology 1/2012 Go to the issue

EditorialNotes

Pheochromocytoma and Paraganglioma: Progress on all Fronts

OriginalPaper

Rationale for Anti-angiogenic Therapy in Pheochromocytoma and Paraganglioma

ReviewPaper

Signaling Pathways in Pheochromocytomas and Paragangliomas: Prospects for Future Therapies

OriginalPaper

Diagnostic Tests and Biomarkers for Pheochromocytoma and Extra-adrenal Paraganglioma: From Routine Laboratory Methods to Disease Stratification

Report

Images in Endocrine Pathology: a Starry-Sky in the Thyroid

Abstracts

The 12th International Pituitary Pathology Meeting
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits